PFS, rather than overallsurvival (OS), was accepted by regulatory authorities in the United States and Europe as the endpoint for approval of bevacizumab for the renal cell carcinoma indication.
欧美权威机构接受PFS作为观察终点，而非总生存期（OS），肾细胞癌作为贝伐单抗的适应症范围。
2
Secondary end points included overallsurvival (OS) and overall response rate (ORR) per IRC.